Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

When it comes to cancer, waiting for symptoms may soon be old news. Telehealth company Hims & Hers began offering a blood test this week that screens for a wide range of cancers before warning signs ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

The Navy has a new fitness test for active-duty “combat arms personnel,” including members of Naval Special Warfare and Naval Special Operations commands. It is called the Navy Combat Fitness Test ...

Add Task & Purpose (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Navy SEAL trainees ...

Marine recruits conduct an initial strength assessment at Marine Corps Recruit Depot San Diego, California, Sept. 6, 2025. (Cpl. Sarah M. Grawcock/U.S. Marine Corps) The U.S. Marine Corps is slated to ...

Diagnosing pancreatic cancer at an early stage is challenging. The signs and symptoms — including abdominal pain, weight loss and indigestion — are often non-specific and shared with benign diseases.

TEXAS – A new wave of blood tests is changing how doctors detect cancer. These tests can find signs of cancer early, sometimes before symptoms appear, giving patients a better chance at successful ...

Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. As part of its bid to transform the future of cancer screening and seize control of ...

Roche, which currently has investigational Alzheimer’s disease drug trontinemab in phase 3 trials, has secured FDA clearance of its blood-based biomarker test for the condition. The minimally invasive ...